Actively Recruiting
Golidocitinib Combined With Selinexor for CAEBVD
Led by Beijing Friendship Hospital · Updated on 2026-01-27
28
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.
CONDITIONS
Official Title
Golidocitinib Combined With Selinexor for CAEBVD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Chronic Active Epstein-Barr Virus Disease (CAEBVD) according to the 2025 consensus guidelines
- Age between 18 and 70 years, any gender
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Liver function tests: AST and ALT ≤ 3 times upper limit of normal; total bilirubin ≤ 2 times upper limit of normal
- Kidney function: serum creatinine ≤ 1.5 times upper limit of normal
- Blood counts: absolute neutrophil count ≥ 1 x 10^9/L; platelet count ≥ 50 x 10^9/L; hemoglobin ≥ 60 g/L
- Coagulation: INR ≤ 2.0; prothrombin time ≤ 1.5 times upper limit of normal
- Women of childbearing potential must have a negative pregnancy test and agree to effective contraception during the study and for 12 months after last dose
- Male participants must agree to use contraception during the study and for 6 months after last dose
- Signed informed consent form
You will not qualify if you...
- Presence of EBV-associated blood diseases or cancers such as hemophagocytic lymphohistiocytosis, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, or gastric cancer
- Previous treatment with any JAK inhibitor
- Use of any investigational drug within 12 weeks before study drug start or participation in another clinical study
- History of other primary cancers within 5 years, except certain locally curable cancers treated successfully
- History of organ transplantation such as liver or kidney transplant
- Planned hematopoietic stem cell transplantation during the study
- Active hepatitis B or C infection, positive HIV test, or history of syphilis
- Major surgery within 4 weeks before starting study drug or planned major surgery during study
- Pregnancy or breastfeeding
- History of severe mental illness or drug abuse
- Uncontrolled infections or major internal bleeding
- Allergy or severe hypersensitivity to study drug components
- Inability to comply with study or follow-up requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Friendship Hospital
Beijing, China
Actively Recruiting
Research Team
J
Jingshi Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here